Comparative diagnostic performance of saliva PCR and dried blood spot PCR for congenital cytomegalovirus detection: a systematic review and meta-analysis
Saliva testing outperforms blood spot screening for detecting congenital infection that causes deafness, offering a better way to identify affected newborns early.
This meta-analysis of 19 studies (103,669 neonates) definitively establishes saliva PCR as the superior modality for newborn cCMV screening, with 95% sensitivity versus 72% for dried blood spot PCR while maintaining near-perfect specificity for both. cCMV is the leading non-genetic cause of sensorineural hearing loss and neurodevelopmental impairment, making this finding directly actionable for universal newborn screening programs.
What the study was
- Study design
- Systematic review and meta-analysis (bivariate random-effects, SROC)
- Population
- Neonates screened for congenital cytomegalovirus (cCMV) infection
- Sample size
- 103669
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- BMC Infectious Diseases
Why it surfaced
Large meta-analysis (103,669 neonates, 19 studies) with definitive statistical separation between saliva PCR and DBS PCR sensitivity (95% vs 72%, p=0.004) for cCMV newborn screening. cCMV is the leading preventable cause of congenital hearing loss; earlier detection enables antiviral therapy (ganciclovir/valganciclovir) that preserves hearing outcomes. Saliva PCR is non-invasive and scalable. Practice-changing for universal newborn screening program design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.